Market Research

Cell Therapy Market Size, Share, & Trends Analysis Report By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, CVD, Dermatology), By Region, And Segment Forecasts, 2023 - 2030

Best Price Guarantee Length Publisher Published Date SKU
from $5,950 120 Pages Grand View Research March, 2023 GV17991296
Best Price Guarantee
Price from $5,950
Length 120 Pages
Publisher Grand View Research
Published Date March, 2023
SKU GV17991296

Cell Therapy Market Size, Share, & Trends Analysis Report By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, CVD, Dermatology), By Region, And Segment Forecasts, 2023 - 2030


Cell Therapy Market Growth & Trends


The global cell therapy market size is expected to reach USD 62.39 billion by 2030, expanding at 14.15% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. The market players are witnessing an increasing interest in the development of advanced therapies that are based on tissue, gene, or cell. Research communities and companies continue to make large investments in the culturing and isolation of a broad range of cell types, such as keratinocytes, chondrocytes, cartilage, stem, dermal papilla, & epithelial cells for the development of novel therapies.

Regulatory authorities such as FDA play a crucial role in the growth of the market by undertaking initiatives related to the development and approval of advanced treatment development as well as restriction of unregulated treatments. In addition, direct cellular reprogramming is attracting interest as a cutting-edge treatment approach because of its advantages such as efficacy and security.

On the other hand, an increase in the number of clinical trials related to advanced therapies is expected to boost the market growth in the coming years. According to data obtained from the American Society of Gene & Cell Therapy, in Q1 2022, 32 non-genetically modified cellular therapy trials were initiated, and 69% of these were in the non-oncology arena. Moreover, according to ClinicalTrials.gov, more than 1800 active cellular therapies are under clinical trial.

Furthermore, key companies operating in the market are undertaking several strategic initiatives such as various agreements, new launches, and expansion to strengthen their market presence. For instance, in May 2022, the University of Pennsylvania's personalized cellular therapy was approved for the treatment of individuals with relapsed or resistant follicular lymphoma.

Moreover, in April 2021, Bristol Myers Squibb declared that U.S. FDA approved its Breyanzi (lisocabtagene maraleucel), a novel CAR T treatment for adults with R/R large B-cell lymphoma. In the pivotal trial for 3L+ LBCL, TRANSCEND NHL 001, Breyanzi showed a 73% overall response rate and a 54% complete response (CR) rate.

Cell Therapy Market Report Highlights

  • Autologous therapy segment dominated the market with the largest revenue share of 60.6% owing to increasing adoption of this therapy type coupled with lower risk of life-threatening complications
  • Allogenic therapy segment is expected to grow significantly in the coming years owing to factors such as high pricing and growth in stem cell banking. Moreover, many companies are preparing to shift their business toward allogenic cell therapy product development
  • Oncology therapeutic area captured the largest market share of 38.23% in 2022 owing to the increasing adoption of advanced cell therapies in the treatment of various types of cancers. Oncology segment is also projected to exhibit the fastest growth rate of 14.95% during the forecast years
  • Cell therapy are also under the investigation for musculoskeletal disorders and has great potential for market growth
  • North America dominated the global cell therapy market owing to the strong regulatory framework, presence of bodies like the International Society for Cellular Therapy, and presence of key operating companies
Please note The report will be delivered in 3-8 business days upon order notification.


Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.1.1 Purchased Database
2.1.2 GVR’s Internal Database
2.2 Data Analysis
2.3 Market Formulation & Validation
2.4 Approaches for Market Estimation
2.4.1 Approach 1: Commodity Flow & Bottom Up Approach
2.4.2 Approach 2: Top Down and Parent Market Analysis
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Rise in number of clinical studies pertaining to the development of cellular therapies
3.1.1.2 Rising adoption of regenerative medicine
3.1.1.3 Introduction of novel platforms and technologies
3.1.2 Market restraint analysis
3.1.2.1 Ethical concerns related to stem cell research
3.1.2.2 Clinical issues pertaining to development & implementation of cell therapy
3.1.2.2.1 Manufacturing issues
3.1.2.2.2 Genetic instability
3.1.2.2.3 Stem cell culture condition
3.1.2.2.4 Stem cell distribution after transplant
3.1.2.2.5 Immunological rejection
3.1.2.2.6 Challenges associated with allogenic mode of transplantation
3.2 Penetration & Growth Prospect Mapping For Therapy Type, 2022
3.3 Cell Therapy Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological)
3.4 Industry Analysis - Porter’s
Chapter 4 Cell Therapy Market Categorization: Therapy Type Estimates & Trend Analysis
4.1 Allogenic Cell Therapy
4.1.1 Global Allogenic Cell Therapy market, 2018 - 2030 (USD Billion)
4.1.2 Stem Cell Therapy
4.1.2.1 Global Allogenic Cell Therapy market for Stem Cell Therapy, 2018 - 2030 (USD Billion)
4.1.2.2 BM, Blood, & Umbilical Cord-derived Stem Cells
4.1.2.2.1 Global Allogenic Cell Therapy market for BM, Blood, & Umbilical Cord-derived Stem Cells, 2018 - 2030 (USD Billion)
4.1.2.3 Adipose Derived Cells
4.1.2.3.1 Global Allogenic Cell Therapy market for Adipose Derived Cells, 2018 - 2030 (USD Billion)
4.1.3 Non-Stem Cell Therapy
4.1.3.1 Global Allogenic Cell Therapy market for Non-Stem Cell Therapy, 2018 - 2030 (USD Billion)
4.1.3.2 T-Cell Therapy
4.1.3.2.1 Global Allogenic Cell Therapy market for T-Cell Therapy, 2018 - 2030 (USD Billion)
4.1.3.3. CAR-T Cell Therapy
4.1.3.3.1 Global Allogenic Cell Therapy market for CAR-T Cell Therapy, 2018 - 2030 (USD Billion)
4.1.3.4 T-Cell Receptor (TCR)
4.1.3.4.1 Global Allogenic Cell Therapy market for T-Cell Receptor (TCR), 2018 - 2030 (USD Billion)
4.1.3.5 Tumor Infiltrating Lymphocytes (TIL)
4.1.3.5.1 Global Allogenic Cell Therapy market for Tumor Infiltrating Lymphocytes (TIL), 2018 - 2030 (USD Billion)
4.1.3.6 Other Therapy
4.1.3.6.1 Global Allogenic Cell Therapy market for Other Therapy, 2018 - 2030 (USD Billion)
4.2 Autologus Cell Therapy
4.1.1 Global Autologus Cell Therapy market, 2018 - 2030 (USD Billion)
4.1.2 Stem Cell Therapy
4.1.2.1 Global Autologus Cell Therapy market for Stem Cell Therapy, 2018 - 2030 (USD Billion)
4.1.2.2 BM, Blood, & Umbilical Cord-derived Stem Cells
4.1.2.2.1 Global Autologus Cell Therapy market for BM, Blood, & Umbilical Cord-derived Stem Cells, 2018 - 2030 (USD Billion)
4.1.2.3 Adipose-Derived Cells
4.1.2.3.1 Global Autologus Cell Therapy market for Adipose Derived Cells, 2018 - 2030 (USD Billion)
4.1.3 Non-Stem Cell Therapy
4.1.3.1 Global Autologus Cell Therapy market for Non-Stem Cell Therapy, 2018 - 2030 (USD Billion)
4.1.3.2 T-Cell Therapy
4.1.3.2.1 Global Autologus Cell Therapy market for T-Cell Therapy, 2018 - 2030 (USD Billion)
4.1.3.3 CAR-T Cell Therapy
4.1.3.3.1 Global Autologus Cell Therapy market for CAR-T Cell Therapy, 2018 - 2030 (USD Billion)
4.1.3.4 T-Cell Receptor (TCR)
4.1.3.4.1 Global Autologus Cell Therapy market for T-Cell Receptor (TCR), 2018 - 2030 (USD Billion)
4.1.3.5 Tumor Infiltrating Lymphocytes (TIL)
4.1.3.5.1 Global Autologus Cell Therapy market for Tumor Infiltrating Lymphocytes (TIL), 2018 - 2030 (USD Billion)
4.1.3.6 Other Therapy
4.1.3.6.1 Global Autologus Cell Therapy market for Other Therapy, 2018 - 2030 (USD Billion)
Chapter 5 Cell Therapy Market Categorization: Therapeutic Area Estimates & Trend Analysis
5.1 Cell Therapy Market: Therapeutic Area Movement Analysis
5.2 Oncology
5.2.1 Global cell therapy market for oncology therapies, 2018 - 2030 (USD Million)
5.3 Cardiovascular Disease (CVD)
5.3.1 Global cell therapy market for cardiovascular disease (CVD) therapies, 2018 - 2030 (USD Million)
5.4 Musculoskeletal Disorders
5.4.1 Global cell therapy market for musculoskeletal disorders therapies, 2018 - 2030 (USD Million)
5.5 Dermatology
5.5.1 Global cell therapy market for dermatology therapies, 2018 - 2030 (USD Million)
5.6 Others
5.6.1 Global cell therapy market for other therapies, 2018 - 2030 (USD Million)
Chapter 6 Cell Therapy Market Categorization: Regional Estimates & Trend Analysis
6.1 North America
6.1.1 SWOT Analysis
6.1.1.1 North America Cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.1.2 U.S.
6.1.2.1 Key country dynamics
6.1.2.2 Target disease prevalence
6.1.2.3 Competitive scenario
6.1.2.4 Regulatory framework
6.1.2.5 Reimbursement scenario
6.1.2.6 U.S. cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.1.3 Canada
6.1.3.1 Key country dynamics
6.1.3.2 Target disease prevalence
6.1.3.3 Competitive scenario
6.1.3.4 Regulatory framework
6.1.3.5 Reimbursement scenario
6.1.3.6 Canada cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.2 Europe
6.2.1 SWOT Analysis:
6.2.1.1 Europe cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.2.2 Germany
6.2.2.1 Key country dynamics
6.2.2.2 Target disease prevalence
6.2.2.3 Competitive scenario
6.2.2.4 Regulatory framework
6.2.2.5 Reimbursement scenario
6.2.2.6 Germany cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.2.3 U.K.
6.2.3.1 Key country dynamics
6.2.3.2 Target disease prevalence
6.2.3.3 Competitive scenario
6.2.3.4 Regulatory framework
6.2.3.5 Reimbursement scenario
6.2.3.6 U.K. cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.2.4 France
6.2.4.1 Key country dynamics
6.2.4.2 Target disease prevalence
6.2.4.3 Competitive scenario
6.2.4.4 Regulatory framework
6.2.4.5 Reimbursement scenario
6.2.4.6 France cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.2.5 Italy
6.2.5.1 Key country dynamics
6.2.5.2 Target disease prevalence
6.2.5.3 Competitive scenario
6.2.5.4 Regulatory framework
6.2.5.5 Reimbursement scenario
6.2.5.6 Italy cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.2.6 Spain
6.2.6.1 Key country dynamics
6.2.6.2 Target disease prevalence
6.2.6.3 Competitive scenario
6.2.6.4 Regulatory framework
6.2.6.5 Reimbursement scenario
6.2.6.6 Spain cell therapy market estimates and f.orecasts, 2018 - 2030 (USD million)
6.2.7 Denmark
6.2.7.1 Key country dynamics
6.2.7.2 Target disease prevalence
6.2.7.3 Competitive scenario
6.2.7.4 Regulatory framework
6.2.7.5 Reimbursement scenario
6.2.7.6 Denmark cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.2.8 Sweden
6.2.8.1 Key country dynamics
6.2.8.2 Target disease prevalence
6.2.8.3 Competitive scenario
6.2.8.4 Regulatory framework
6.2.8.5 Reimbursement scenario
6.2.8.6 Sweden cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.2.9 Norway
6.2.9.1 Key country dynamics
6.2.9.2 Target disease prevalence
6.2.9.3 Competitive scenario
6.2.9.4 Regulatory framework
6.2.9.5 Reimbursement scenario
6.2.9.6 Norway cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.2.10 Rest Of Europe cell therapy market Estimates And Forecasts, 2018 - 2030 (USD million)
6.3 Asia Pacific
6.3.1 SWOT Analysis:
6.3.1.1 Key Region Dynamics
6.3.1.2 Asia Pacific cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.3.2 Japan
6.3.2.1 Target disease prevalence
6.3.2.2 Competitive scenario
6.3.2.3 Regulatory framework
6.3.2.4 Reimbursement scenario
6.3.2.5 Japan cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.3.3 China
6.3.3.1 Target disease prevalence
6.3.3.2 Competitive scenario
6.3.3.3 Regulatory framework
6.3.3.4 Reimbursement scenario
6.3.3.5 China cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.3.4 India
6.3.4.1 Target disease prevalence
6.3.4.2 Competitive scenario
6.3.4.3 Regulatory framework
6.3.4.4 Reimbursement scenario
6.3.4.5 India cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.3.5 South Korea
6.3.5.1 Target disease prevalence
6.3.5.2 Competitive scenario
6.3.5.3 Regulatory framework
6.3.5.4 Reimbursement scenario
6.3.5.5 South Korea cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.3.6 Australia
6.3.6.1 Target disease prevalence
6.3.6.2 Competitive scenario
6.3.6.3 Regulatory framework
6.3.6.4 Reimbursement scenario
6.3.6.5 Austrlia cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.3.7 Thailand
6.3.7.1 Target disease prevalence
6.3.7.2 Competitive scenario
6.3.7.3 Regulatory framework
6.3.7.4 Reimbursement scenario
6.3.7.5 Thailand cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.3.8 Rest of Asia Pacific cell therapy market Estimates And Forecasts, 2018 - 2030 (USD million)
6.4 Latin America
6.4.1 SWOT Analysis
6.4.2 Key Regional Dynamics
6.4.2.1 Latin America cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.4.3 Brazil
6.4.3.1 Target disease prevalence
6.4.3.2 Competitive scenario
6.4.3.3 Regulatory framework
6.4.3.4 Reimbursement scenario
6.4.3.5 Brazil cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.4.4 Mexico
6.4.4.1 Target disease prevalence
6.4.4.2 Competitive scenario
6.4.4.3 Regulatory framework
6.4.4.4 Reimbursement scenario
6.4.4.5 Mexico cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.4.5 Argentina
6.4.5.1 Target disease prevalence
6.4.5.2 Competitive scenario
6.4.5.3 Regulatory framework
6.4.5.4 Reimbursement scenario
6.4.5.5 Argentina cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.4.6 Rest Of Latam cell therapy market Estimates And Forecasts, 2018 - 2030 (USD million)
6.5 Middle East & Africa (MEA)
6.5.1 SWOT Analysis
6.5.2 KEY regional DYNAMICS
6.5.2.1 Middle East & Africa cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.5.3 South AfricaA
6.5.3.1 Target disease prevalence
6.5.3.2 Competitive scenario
6.5.3.3 Regulatory framework
6.5.3.4 Reimbursement scenario
6.5.3.5 South Africa cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.5.4 Saudi Arabia
6.5.4.1 Target disease prevalence
6.5.4.2 Competitive scenario
6.5.4.3 Regulatory framework
6.5.4.4 Reimbursement scenario
6.5.4.5 Saudi Arabia cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.5.5 UAE
6.5.5.1 Target disease prevalence
6.5.5.2 Competitive scenario
6.5.5.3 Regulatory framework
6.5.5.4 Reimbursement scenario
6.5.5.5 UAE cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.5.6 Kuwait
6.5.6.1 Target disease prevalence
6.5.6.2 Competitive scenario
6.5.6.3 Regulatory framework
6.5.6.4 Reimbursement scenario
6.5.6.5 Kuwait cell therapy market estimates and forecasts, 2018 - 2030 (USD million)
6.5.7 Rest of MEA cell therapy market Estimates and Forecasts, 2018 - 2030 (USD million)
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Company Profiles
7.2.1 Kolon TissueGene, Inc.
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 JCR Pharmaceuticals Co., Ltd.
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Product benchmarking
7.2.2.4 Strategic initiatives
7.2.3 MEDIPOST
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Osiris Therapeutics, Inc.
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Product benchmarking
7.2.4.4 Strategic initiatives
7.2.5 Stemedica Cell Technologies, Inc.
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 Cells for Cells
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 NuVasive, Inc
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 Fibrocell Science, Inc.
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Vericel Corporation
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives
7.2.10 PHARMICELL Co., Ltd
7.2.10.1 Company overview
7.2.10.2 Financial performance
7.2.10.3 Product benchmarking
7.2.10.4 Strategic initiatives
7.2.11 ANTEROGEN.CO.,LTD
7.2.11.1 Company overview
7.2.11.2 Financial performance
7.2.11.3 Product benchmarking
7.2.11.4 Strategic initiatives
7.2.12 Celgene Corporation
7.2.12.1 Company overview
7.2.12.2 Financial performance
7.2.12.3 Product benchmarking
7.2.12.4 Strategic Initiatives

$5,950
$6,950
$8,950

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings